Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Actinium Pharmaceuticals (ATNM) Income from Continuing Operations (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Income from Continuing Operations for 8 consecutive years, with 2296000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations changed N/A to 2296000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 30243000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at 33289000.0 for FY2025, 12.95% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 2296000.0 at Actinium Pharmaceuticals, up from 5131000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 2296000.0 in Q4 2025, with the low at 15938000.0 in Q1 2025.
  • Average Income from Continuing Operations over 5 years is 8961421.05, with a median of 8670000.0 recorded in 2024.
  • The sharpest move saw Income from Continuing Operations crashed 124.32% in 2023, then skyrocketed 55.64% in 2025.
  • Over 5 years, Income from Continuing Operations stood at 8048000.0 in 2021, then crashed by 40.3% to 11291000.0 in 2022, then grew by 17.42% to 9324000.0 in 2023, then fell by 24.07% to 11568000.0 in 2024, then soared by 80.15% to 2296000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 2296000.0, 5131000.0, and 6878000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.